Market research
AKTX Akari Therapeutics PLC
NASDAQ USD Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 17M
- P/E ratio
- Not available
- Analyst target
- 25.5
- Dividend yield
- Not available
- Beta
- 1.44
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 17M
- P/E ratio
- Not available
- Analyst target
- 25.5
- Dividend yield
- Not available
- Beta
- 1.44
About
About Akari Therapeutics PLC
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
Research context
Akari Therapeutics PLC appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the AKTX discussion.
5 years, 6 months ago
Akari Therapeutics, Plc is currently in a long term downtrend where the price is trading 24.9% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Akari Therapeutics, Plc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 156.2% to $1M since the same quarter in the previous year.
Finally, its free cash flow grew by 85.7% to $-704K since the same quarter in the previous year.
Based on the above factors, Akari Therapeutics, Plc gets an overall score of 3/5.